全文获取类型
收费全文 | 417篇 |
免费 | 27篇 |
国内免费 | 61篇 |
学科分类
医药卫生 | 505篇 |
出版年
2022年 | 3篇 |
2021年 | 13篇 |
2020年 | 3篇 |
2019年 | 7篇 |
2018年 | 6篇 |
2017年 | 6篇 |
2016年 | 4篇 |
2015年 | 12篇 |
2014年 | 8篇 |
2013年 | 11篇 |
2012年 | 9篇 |
2011年 | 9篇 |
2010年 | 14篇 |
2009年 | 21篇 |
2008年 | 5篇 |
2007年 | 45篇 |
2006年 | 17篇 |
2005年 | 16篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 5篇 |
2000年 | 7篇 |
1999年 | 13篇 |
1998年 | 28篇 |
1997年 | 37篇 |
1996年 | 26篇 |
1995年 | 22篇 |
1994年 | 12篇 |
1993年 | 24篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 19篇 |
1988年 | 7篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 4篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 12篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1966年 | 1篇 |
1960年 | 1篇 |
1959年 | 1篇 |
1903年 | 1篇 |
排序方式: 共有505条查询结果,搜索用时 15 毫秒
21.
22.
Daniel P. Potaczek Sebastian D. Unger Nan Zhang Styliani Taka Sven Michel Nesibe Akdağ Feng Lan Markus Helfer Christoph Hudemann Markus Eickmann Chrysanthi Skevaki Spyridon Megremis Anne Sadewasser Bilal Alashkar Alhamwe Fahd Alhamdan Mübeccel Akdis Michael R. Edwards Sebastian L. Johnston Harald Renz 《The Journal of allergy and clinical immunology》2019,143(4):1403-1415
23.
24.
The initial management of bladder outflow obstruction typically related to benign prostatic hyperplasia (BPH) falls to a large extent within the remit of general practice. Referral onwards to secondary care typically arises following the failure to respond to conservative measures or when complications have supervened; the most significant of which is urinary retention. In the hospital setting, anaesthesia, constipation and immobility are the common precipitants. What follows is a practical guide to the management of these situations and provides an overview of the conservative, medical, minimally invasive and surgical treatments available. 相似文献
25.
26.
Incidence, clinical significance and prognosis of ventricular fibrillation in the early phase of myocardial infarction 总被引:1,自引:1,他引:1
DUBOIS CH.; SMEETS J. P.; DEMOULIN J. CL.; PIERARD L.; FOIDART G.; HENRARD L.; TULIPPE CH.; PRESTON L.; CARLIER J.; KULBERTUS H. E. 《European heart journal》1986,7(11):945-951
Of 1265 patients admitted to the CCU with the diagnosis of acuteMI, 96 (7.6%) developed ventricular fibrillation within 72 hoursfollowing admission. Of these 96, 35 (36.5%) had secondary VFassociated with left ventricular failure; they had a high in-hospitalmortality of 57.1%. The remaining 61 (63.5%) had primary VF,i.e. VF occurring in the absence of significant LV failure.Fourteen of these (23%) died in hospital: 9 due to PVF (3 duringthe first episode, 6 during a recurrence). This mortality figurewas significantly higher (P<0.001) than the mortality of10% seen among patients who did not experience VF. Primary VFshowed a recurrence rate of 20%. Compared with the 1061 patientswho left the hospital without primary VF, the 61 subjects withthis rhythm disorder were older, had larger infarcts and morefrequent complications, such as pericarditis, conduction abnormalities,frequent ventricular premature contractions and signs of rightventricular failure. These findings, in contrast with a widelyheld view, suggest that primary VFmay carry a guarded prognosis. 相似文献
27.
H Vrielink ; HW Reesink ; HL Zaaijer ; CL van der Poel; HT Cuypers ; PN Lelie 《Transfusion》1996,36(4):344-346
BACKGROUND: Assays that detect human T-lymphotropic virus type I and type II antibody (HTLV-I/II) are widely used in the routine screening of blood donors. STUDY DESIGN AND METHODS: Four commercially available anti-HTLV-I (Fujirebio and Organon Teknika) or -HTLV-I/II assays (Murex and Ortho) were evaluated in various serum panels: A) HTLV-I-positive specimens (n = 41), confirmed by Western blot and polymerase chain reaction; B) a commercially available anti-HTLV-I/II panel; C) serial dilutions of sera from HTLV-I-positive individuals (n = 30), confirmed by immunofluorescence assay and Western blot: D) serial dilutions of HTLV-II-positive blood donors (n = 20), confirmed by Western blot and polymerase chain reaction, and E) sera from first-time blood donors (n = 1055). RESULTS: All four assays elicited reactions in all 82 HTLV-I- positive samples in Panels A, B, and C. Of 32 HTLV-II-positive specimens in Panels B and D, 31 (96.9%) reacted in the Organon Teknika assay and all 32 reacted in the remaining tests. Probit analysis of test results in Panels C and D indicated that the Fujirebio test was the most sensitive assay, followed by Organon Teknika, Ortho, and Murex. The specificities of Fujirebio, Murex, Organon Teknika, and Ortho tests in 1055 first-time blood donors were 99.9, 100, 99.6, and 99.9 percent, respectively. CONCLUSION: All four studied assays for detecting HTLV-I or HTLV-I/II antibodies are appropriate as screening tests. 相似文献
28.
C. L. Skevaki I. Christodoulou I. S. Spyridaki I. Tiniakou V. Georgiou P. Xepapadaki D. A. Kafetzis N. G. Papadopoulos 《Clinical and experimental allergy》2009,39(11):1700-1710
Background Rhinoviruses (RVs) are responsible for the majority of acute asthma and chronic obstructive pulmonary disease (COPD) exacerbations. RVs infect the lower airways and induce the production of pro-inflammatory and remodelling-associated mediators. Budesonide (BUD) and formoterol (FORM) synergize in controlling asthma and COPD exacerbations; however, their effects on virus-induced inflammation and remodelling are less known.
Objective We investigated whether BUD and FORM synergize in suppressing RV-induced inflammation and remodelling in the airways.
Methods In vitro models of RV infection of BEAS-2B and primary normal human bronchial epithelial (NHBE) cells were used. We assessed the effects of individual and combined drugs administered post-infection, at a clinically relevant concentration range (10−6 –10−10 m ), on the production of CCL5, CXCL10, CXCL8, IL-6 and the remodelling-associated VEGF and bFGF, using ELISA and RT-PCR.
Results BUD effectively suppressed RV-mediated induction of all mediators studied, in a concentration-dependent manner. FORM alone suppressed the production of CXCL8 and bFGF. The combination of BUD and FORM had concentration-dependent, additive or synergistic effects in the suppression of RV-induced CCL5, CXCL8 and CXCL10 in both cell types as well as VEGF in NHBE only. Combination treatment also resulted in an enhanced suppression of RV-induced IL-6, and CCL5 at the mRNA level as compared with BUD or FORM alone.
Conclusion BUD and FORM suppress RV-induced chemokines and growth factors in bronchial epithelial cells in a concentration-dependent, synergistic or additive manner. These data further support the combined use of BUD and FORM in asthma and COPD and intensification of this therapy during exacerbations. 相似文献
Objective We investigated whether BUD and FORM synergize in suppressing RV-induced inflammation and remodelling in the airways.
Methods In vitro models of RV infection of BEAS-2B and primary normal human bronchial epithelial (NHBE) cells were used. We assessed the effects of individual and combined drugs administered post-infection, at a clinically relevant concentration range (10
Results BUD effectively suppressed RV-mediated induction of all mediators studied, in a concentration-dependent manner. FORM alone suppressed the production of CXCL8 and bFGF. The combination of BUD and FORM had concentration-dependent, additive or synergistic effects in the suppression of RV-induced CCL5, CXCL8 and CXCL10 in both cell types as well as VEGF in NHBE only. Combination treatment also resulted in an enhanced suppression of RV-induced IL-6, and CCL5 at the mRNA level as compared with BUD or FORM alone.
Conclusion BUD and FORM suppress RV-induced chemokines and growth factors in bronchial epithelial cells in a concentration-dependent, synergistic or additive manner. These data further support the combined use of BUD and FORM in asthma and COPD and intensification of this therapy during exacerbations. 相似文献
29.
Wang LM Zhang Q Zhu W He C Lu CL Ding DF Chen ZY 《第二军医大学学报》2005,26(11):1299-1299
Glial cell line-derived neurotrophic factor (GDNF) plays a critical role in neurodevelopment and survival of midbrain dopaminergic and spinal motor neurons in vitro and in vivo. The biological actions of GDNF are mediated by a two-receptor complex consisting of a glycosylphosphatidylinositol-linked cell surface molecule, the GDNF family receptor alpha 1 (GFR alpha 1), and receptor protein tyrosine kinase Ret. Although structural analysis of GDNF has been extensively examined, less is known about the structural basis of GFR alpha 1 function. In this study, based on evolutionary trace method and relative solvent accessibility prediction of residues, a set of trace residues that are solvent-accessible was selected for site-directed mutagenesis. A series of GFR alpha 1 mutations was made, and PC12 cell lines stably expressing different GFR alpha 1 mutants were generated. According to the survival and differentiation responses of these stable PC12 cells upon GDNF stimulation and the GDNF- GFR alpha 1-Ret interaction assay, residues 152NN153, Arg259, and 316SNS318 in the GFR alpha 1 central region were found to be critical for GFR alpha 1 binding to GDNF and eliciting downstream signal transduction. The single mutation R259A in the GFR alpha 1 molecule simultaneously lost its binding ability to GDNF and Ret. However N152A/N153A or S316A/N317A/ S318A mutation in the GFR alpha 1 molecule still retained the ability to bind with Ret. These findings suggest that distinct structural elements in GFR alpha 1 may be involved in binding to GDNF and Ret. 相似文献
30.